

Screening for tobacco and cannabis use by general practitioners: a French nationwide representative survey

Tangui Barré, Vincent Di Beo, Abbas Mourad, Patrizia Carrieri, Gwenaëlle Maradan, Lisa Fressard, Thomas Herault, Jean-François Buyck, Pierre Verger, François Beck

▶ To cite this version:

Tangui Barré, Vincent Di Beo, Abbas Mourad, Patrizia Carrieri, Gwenaëlle Maradan, et al.. Screening for tobacco and cannabis use by general practitioners: a French nationwide representative survey. International Journal of Mental Health and Addiction, 2024, 10.1007/s11469-024-01299-9. hal-04588762

HAL Id: hal-04588762 https://hal.science/hal-04588762v1

Submitted on 27 May 2024 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Screening for tobacco and cannabis use by general practitioners: a French nationwide representative survey

Tangui Barré¹, Vincent Di Beo¹, Abbas Mourad¹, Patrizia Carrieri¹, Gwenaëlle Maradan², Lisa Fressard², Thomas Herault³, Jean-François Buyck⁴, Pierre Verger^{2*}, François Beck^{5,6*}

*These authors contributed equally to this work

¹Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France

² ORS PACA, Southeastern Health Regional Observatory, Marseille, France

³Union Régionale des Médecins Libéraux des Pays de La Loire, Nantes, France

⁴Observatoire Régional de La Santé Des Pays de La Loire, Nantes, France

⁵Santé Publique France, Saint-Maurice, France

⁶Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Inserm U1018, Université Paris-Saclay, Université Paris-Sud, Université Versailles Saint-Quentin (UVSQ), Villejuif, France

Correspondence to: Patrizia Carrieri, pmcarrieri@aol.com

Running title : Tobacco screening by general practitioners

Declarations

Conflict of Interest

All authors declare they have no conflict of interest.

Informed consent

The survey was conducted in accordance with the Declaration of Helsinki. In line with French law, no written consent was required as the survey was anonymous.

Role of Funding Source

The study was funded by Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques (DREES)/Ministere des solidarites et de la santé; Caisse Nationale d'Assurance Maladie; Haute Autorite de santé. These funding sources had no role in the writing of the manuscript or in the decision to submit it for publication.

Contributors

Conceptualization: TB, PC, PV, FB

Methodology: TB, AM, VDB, LF, PV Formal analysis: VDB, LF Investigation: GM, TH, JFB, PV Writing - Original Draft: TB Writing - Review & Editing: all authors

Acknowledgements

We would like to thank the study participants. Thank you also to Jude Sweeney (Milan, Italy) for the English revision and copyediting of our manuscript.

Data availability statement

Data are not publicly available due to privacy/ethical restrictions.

Abstract

Screening is a crucial step in the cascade of care for people who smoke tobacco or cannabis. In France, general practitioners (GPs) are considered a pillar of tobacco control, and under National Authority of Health guidelines, they are expected to systematically screen their patients for tobacco use. We aimed to assess the frequency of tobacco and cannabis use screening by French GPs and to identify characteristics associated with more frequent screening.

From a nationwide random sample of GPs, we estimated the prevalence of selfreported systematic tobacco and cannabis screening. Using logistic regression models, we identified characteristics of GPs associated with systematic screening.

Our study sample comprised 2412 GPs, 74.6% of whom systematically screened their patients for tobacco use, and 34.7% for cannabis use. Systematic tobacco screening was associated with being under 50 years of age, working in a group practice, and using the 'early identification and brief intervention' approach. Systematic cannabis screening was associated with being 50-59 years old, and using the 'early identification and brief intervention' approach.

This study highlighted improvements in tobacco and cannabis screening frequencies in comparison to previous French data. Better GP training is an essential lever to ensure these positive trends continue.

Keywords: tobacco; cannabis; screening; general practitioner; France.

Introduction

In 2015, tobacco smoking accounted for 11.5% of global deaths (GBD 2015 Tobacco Collaborators, 2017). In Europe, the smoking-attributable mortality rate in men and women has been forecast to reach 11% and 10%, respectively, by 2040 (Janssen, El Gewily, & Bardoutsos, 2021). In France, the proportion of people aged 18-75 years old who were daily tobacco smokers remained stable at 24.5% between 2019 and 2022 (Pasquereau et al., 2023). These figures highlight the need for interventions to lower this prevalence in order to reduce the overall health burden of tobacco smoking. As part of its 2018-2022 national tobacco control program, France set the target of a smoke-free (<5% prevalence) generation by 2032 (Ministère des Solidarités et de la Santé & Ministère de l'Action et des Comptes publics, 2018).

Article 14 of the World Health Organization (WHO) Framework Convention on Tobacco Control stipulates that "each Party [...] shall take effective measures to promote cessation of tobacco use and adequate treatment for tobacco dependence" (World Health Organization, 2013, p. 14). The 5A's model (Ask, Advise, Assess, Assist, Arrange) summarize the activities which primary care providers can implement to facilitate tobacco smoking cessation within 3 to 5 minutes in a primary care setting (World Health Organization, 2014). Screening (i.e., 'Ask) is the first of these activities, and may lead to a brief intervention. Such interventions are cost-effective and recommended (Barbosa et al., 2022; Haute Autorité de Santé, 2021; Solberg, Maciosek, Edwards, Khanchandani, & Goodman, 2006).

Primary care physicians are in a unique position to help smokers. In a systematic review, Bartsch et al. found that 65% of primary care physicians applied the 'Ask' step of the 5A's model (Bartsch, Härter, Niedrich, Brütt, & Buchholz, 2016); this step constitutes screening. In its 2014 guidelines (Haute Autorité de Santé, 2014a) (updated in 2023 (Haute Autorité de Santé, 2023)) for primary care healthcare professionals, the French National Authority for Health stated that "individual tobacco smoking screening should be systematic".

In general populations, cannabis use is associated with an increased risk of psychosis onset, and with poorer health outcomes in people who already present psychosis. It is also associated with higher risks of psychiatric symptoms such as depression and mania (Solmi et al., 2023); younger users are particularly vulnerable to these risks. Cannabis use is also associated with motor vehicle accidents (Solmi et al., 2023). Approximately 30% of cannabis

users may develop cannabis use disorder (CUD) (Feingold, Livne, Rehm, & Lev-Ran, 2020; van der Pol et al., 2013). Recent trends in Europe and the US point to an increase in the prevalence of cannabis use disorder (CUD) (Manthey, 2019; United Nations Office on Drugs and Crime, 2020). In France, the estimated age-standardized prevalence rate per 100,000 persons in 2019 was 705.2 (versus 303.4 globally) (Shao et al., 2023). According to the Global Burden of Disease 2019, cannabis use disorders were associated with 690 000 disability-adjusted life years globally, with younger adults being the most impacted (Shao et al., 2023). In 2021, an estimated 10.6% of 18-64 year-olds in France had used cannabis in the previous year, unchanged since 2017. Specifically, this rate was 23.5% in 18-24 year-old individuals (Le Nézet, Spilka, Lahaie, & Andler, 2022). Increasing cannabis use screening in primary care is therefore likely to yield significant public health benefits, especially regarding mental health outcomes among younger users (Degenhardt et al., 2013; Laporte et al., 2017; Richards et al., 2019).

In France, every patient is expected to choose his/her primary care physician (generally a general practitioner, GP) and to declare this choice to the Social Security system. This physician is the main entry point for general care and is expected to know the medical history of his/her patients, and to refer patients to specialists if needed. Patients must go through their primary care physician to see a specialist if they wish to optimize their healthcare reimbursement. The frequency of visits to GP and the established patient-GP relationship make these professionals excellent candidates for the detection of at-risk behaviors (Zwar & Richmond, 2006). However, in 2008-2009, only 63.2% of French GPs systematically screened their patients at least once for tobacco use (Beck, Guignard, Obradovic, Gautier, & Karila, 2011) and only 7.8% for cannabis use (Beck et al., 2011).

Tobacco screening frequency varies according to patient and GP characteristics (Andler, Cogordan, Pasquereau, Buyck, & Nguyen-Thanh, 2018; Delpech et al., 2020; Nelson et al., 2015; Rosell-Murphy et al., 2015). In order to improve the cascade of primary care, there is a need to identify a) which GP characteristics are associated with better (i.e., more systematic) screening practices, not only of tobacco use but also cannabis use, and b) GP-perceived barriers to implementing screening (van Rossem et al., 2015; Vogt, Hall, & Marteau, 2005). GP characteristics previously associated with tobacco screening and preventive practices include personal characteristics such as gender (Delpech et al., 2020), professional characteristics such as training (Andler et al., 2018), and practice-related characteristics such as the number of GP patients with alcohol use disorder (Costa et al.,

2019). Tobacco screening is one preventive activity which GPs may not have enough time to implement (Coindard et al., 2022; Yarnall, Pollak, Østbye, Krause, & Michener, 2003). One possible reason for this is a heavy workload. On the contrary, having a greater interest in preventative activities in general may favor tobacco screening; indeed, some GPs choose to adapt their practice by allocating dedicated time to prevention activities (Holmberg et al., 2014).

In this context, we aimed to assess the frequency of tobacco and cannabis use screening by GPs in France, and to identify GP characteristics associated with more frequent screening. We also sought to explore the reasons for patient-GP communication difficulties concerning tobacco use reduction and cessation.

Materials and methods

Study participants

We used data from the third wave (December 2019 to March 2020) of the 4th edition (2018-2022) of the multi-year French Observational Panel on Practices and Conditions of General medicine (*Le panel d'observation des pratiques et des conditions d'exercice en médecine générale*) (David, Buyck, & Metten, 2021; Direction de la recherche, des études, de l'évaluation et des statistiques, 2020). Data collection targeted GPs who met all the following criteria: i) derived all or part of their income from private practice, ii) professionally active on 1 January 2018, iii) not exclusively practicing a specialty which is not officially recognized by the Social Security system (e.g. acupuncture, homeopathy, addiction medicine, psychotherapy), and iv) working as a primary care physician for at least 200 patients on 1 January 2018.

Physicians were drawn at random from the national directory of health professionals (*Répertoire Partagé des Professions de Santé*), with stratification by gender, age class (under 50, 50 to 59, and 60 or older), volume of activity category (understood here as the number of consultations made in 2017 (below the first quartile, between the first and third quartile, and above the third quartile)), GP supply density (in consultations per year per inhabitant (Vergier, Chaput, & Lefebvre-Hoang, 2017)), and region of practice.

The survey was conducted in accordance with the Declaration of Helsinki. In line with French law, no written consent was required as the survey was anonymous.

Data collection and survey content

Data collection occurred in two phases. First, 83.3% of the expected study sample were solicited over the internet. Approximately one month later, the 16.7% not initially solicited over the internet were solicited by phone to participate using computer-assisted telephone interviewing, as were those previously solicited who had not responded online. Overall, 62% of participants responded online (David et al., 2021).

The third wave of the 4th edition of the panel asked GPs about their opinions and practices in terms of prevention, first globally, and then in terms of preventing addictive behaviors. The survey content was based on a previous survey (Beck et al., 2011) and approved by scientific collaborators including GPs.

Gender and age class were the two sociodemographic characteristics collected. GPs were asked if they had a university diploma in addiction medicine or tobacco care (Yes/No), and if they were familiar with the 'early identification and brief intervention' (*Repérage Précoce et Intervention Brève*, called RPIB in French) for the screening and care of persons using tobacco, alcohol or cannabis (Yes, and you implement it for patients using at least one of these three substances / Yes, but you do not use it / No, you are not familiar with it). The RPIB is recommended by the National Authority for Health (Haute Autorité de Santé, 2014b). In addition to volume of activity category and GP supply density, the questionnaire collected data on whether the GP worked in an individual or group practice. Involvement in prevention activities was assessed using two items: 'In the last two years, have you contributed to the organization of collective preventative activities as part of your professional activity?', and 'Do you display prevention messages and associated material in your office in the form of flyers, booklets, self-administered questionnaires, or videos?' (Yes/No).

GPs were also asked if they personally felt comfortable discussing tobacco reduction or cessation with patients (Yes, absolutely/Yes, somewhat /No, not really/No, absolutely not). A similar question was asked for alcohol use. Those who answered 'No' (either of the two related modalities) to *either* question were then asked to indicate the difficulties they felt in those discussions - *without distinction* between alcohol and tobacco - from a list of ten possibilities (several choices possible). GPs were also asked if they considered that it is part of the physician's role to *initiate* discussions with patients identified as tobacco smokers in order to help them quit (Yes, absolutely/Yes, somewhat /No, not really/No, absolutely not). In addition, they were asked whether existing monetary incentives based on public health objectives (*rémunération sur objectifs de santé publique*, called ROSP in French) had

7

encouraged them to propose the RPIB to tobacco users and at-risk drinking patients more often (Yes/No/Not aware this incentive existed).

Study outcome definitions

The two study outcomes for the present analysis were based on the following questions: i) "How often do you screen your patients for tobacco use?", and ii) "How often do you screen your patients for cannabis use?". Possible answers were: Systematically and repeatedly for all patients/Systematically but only once per patient/Only for certain patients that I consider to be at risk (warning signs, life events, etc.)/I never screen for consumption of this substance/I don't know/I refuse to answer. The two first modalities were merged into a 'systematic screening' modality for the regression models.

Statistical analyses

Respondents' data were weighted using calibration on margins (Vanheuverzwyn & Roy, 2001) for non-return (i.e., GP contacted but not reached) and non-response (GP solicited but declined participation). Data were adjusted for stratification variables (age, volume of activity category, gender, region of practice, and GP supply density in area of practice). Weighting these data ensured that the sample was representative of the target population with respect to these variables. We described the study sample characteristics according to the answers given for the two outcome questions using the Chi-square test on weighted data.

Participants who answered 'I don't know' and 'I refuse to answer' were excluded from the logistic regressions, which we performed on weighted data to identify factors associated with systematic screening (once or repeatedly) of tobacco and cannabis use, separately. The reference answer was therefore non-systematic screening (i.e., 'only for certain patients' or 'I never screen for consumption of this substance').

In line with previous findings in the literature, we considered personal and professional GPs' characteristics, practice-related characteristics, and prevention-related characteristics in our models. The following variables were tested as explanatory variables: age, gender, diploma in addiction medicine or tobacco care, familiarity with the RPIB, volume of activity, GP supply density, individual or group practice, and involvement in prevention activities. Only variables with a liberal p-value < 0.20 (Wald test) in the univariable analyses were considered eligible for the multivariable models. The final multivariable models were built using a backward procedure, and the likelihood ratio test (p-value < 0.05) was used to define the variables to retain in the final models.

Analyses were performed with Stata software version 17.0 (StataCorp LP, College Station, TX, USA).

Results

Study sample characteristics

The response rate was 73%. The study sample comprised 2412 GPs, 61.2% of whom were men, and 39.6% were in the 50-59 age class (**Table 1**). In the whole study sample, 1.1% and 8.8% of respondents declared never screening for tobacco or cannabis use, respectively. By contrast, 23.0% and 54.8% screened only certain patients, 9.4% and 11.3% screened each patient once, and 65.2% and 23.3% systematically and repeatedly screened their patients for tobacco and cannabis use, respectively.

Of the 1884 GPS who screened their patients systematically (once or repeatedly) for tobacco use, 1766 also screened their patients for cannabis use (972 only certain patients, and 794 systematically).

Factors associated with screening frequency

The study sample for the tobacco screening frequency regression comprised 2382 GPs, of whom 75.5% screened their patients systematically (once or repeatedly). After multiple adjustment, systematic tobacco screening was associated with being < 50 years old, working in a group practice, and being familiar with and using the RPIB approach (**Table 2**).

The study sample for the cannabis screening frequency regression comprised 2365 GPs, of whom 35.3% screened their patients systematically (once or repeatedly). After multiple adjustment, systematic cannabis screening was associated with being 50-59 (as compared to <50) years old, and being familiar with and using the RPIB approach (**Table 2**).

Self-reported barriers and levers to screening

With regard to the question on how comfortable they felt discussing tobacco reduction or cessation with patients, 79.9% of the sample answered 'Yes, absolutely', and 17.9% answered 'Yes, somewhat' (**Table 3**). Participants feeling absolutely comfortable were more likely to screen systematically for both substances. **Figure 1** shows the reasons (from the list of 10) given by the 48 GPs who responded with a 'No' modality to this question. The three most cited reasons were not feeling sufficiently trained, patient denial about having at-risk use, and lack of self-efficacy to change patients' behavior.

With regard to the question on whether they considered that it is part of the physician's role to *initiate* discussions with patients identified as tobacco smokers in order to help them reduce or quit their consumption, 80.7% of the sample answered 'Yes, absolutely', and 17.2% answered 'Yes, somewhat'. Participants who replied 'Yes, absolutely' were more likely to systematically screen for both substances (**Table 3**).

In terms of the self-reported effects of state monetary incentives to screen patients more often for tobacco or alcohol use, 34.8% of participants responded 'Yes', while 1.5% responded that they were not aware this incentive existed. Participants who answered 'Yes' were more likely to systematically screen for tobacco use (**Table 3**).

Discussion

In this nationwide French study, three-quarters (74.6%) of our sample of French GPs declared they systematically screened their patients for tobacco use, but only one-third (34.6%) did so for cannabis use. Using the RPIB approach was associated with systematic screening for both substances.

The systematic tobacco screening rate (i.e., at least once) was higher than that observed in the 2008-2009 edition of another French representative survey, the GP Health Barometer, which showed that 63.2% of GPs systematically screened (i.e., at least once) their patients for tobacco use (Beck et al., 2011). This reflects our findings that the overwhelming majority of GPs felt comfortable discussing tobacco consumption, and endorsed the role of GPs in initiating discussion about consumption. These results are also in line with previous findings in the French context which highlighted that GPs i) felt they were able to manage their patients' tobacco use (Rouillon et al., 2021), ii) easily approached the question of tobacco use (Teoli, Haller, Ingrand, & Binder, 2016), and iii) considered they had a prominent role in tobacco reduction (Coindard et al., 2022). Given that tobacco screening could constitute an entry point in care to address alcohol use disorder (Costa et al., 2020), these high screening rates may have implications for the management of other addictive behaviors. Note that this trend reflected that observed for alcohol screening (Barré, Di Beo, Roux, et al., 2023).

The increase in tobacco screening rates in our study in comparison with the 2008-2009 data may be at least partly related to national campaigns. At a societal level, the fight against tobacco in France has been the subject of targeted plans, and has been included in successive national cancer plans. Legislative changes to French healthcare implemented in 2004

(Paraponaris, 2007; The French Parliament, 2004a, p. 806, 2004b) placed GPs at the center of public health care and health prevention. The National Authority of Health guidelines (Haute Autorité de Santé, 2014a, 2023) and the 2014-2019 national tobacco reduction program (Ministère des Affaires sociales, de la Santé et des Droits des femmes, 2014), recognized GPs as a pillar in the fight against tobacco use - as it may be the case in other countries (Zwar & Richmond, 2006). Moreover, in 2012, the ROSP was established. Through the national health insurance system (*Assurance maladie*), the ROSP grants GPs financial bonuses based on self-reported indicators of public health objectives (Assurance Maladie, 2023). GPs who provide RPIB to at least 60% of their tobacco user patients earn ROSP points, which are later translated into money. Although the effectiveness of this incentive remains to be demonstrated (Coleman, 2010), in our study, a third of participating GPs reported that these incentives motivated them to screen more often for tobacco or alcohol use.

Despite the temporal increase in screening rates we observed between the 2008-2009 and 2019-2020 data, another study, conducted in 2017 on a representative sample of French adults, found that only 36.7% of participants who had visited their GP in the previous 12 months reported discussing tobacco use with him/her (Cogordan et al., 2020). It would seem therefore, that while three quarters of GPs in our study applied the National Authority of Health guidelines on systematic screening (Haute Autorité de Santé, 2014a), there remains room for improvement to reach systematic tobacco screening.

The improving trend in tobacco screening frequency we observed in GPs between 2008-2009 and 2019-2020 cannot easily be compared to data from studies in other countries, because of different methodologies, targeted participants, and study periods. Nevertheless, available data from various studies in the U.S. can serve as indicators. Dai & Clements found that the prevalence of tobacco screening in adolescents increased between 2011 to 2013, and then plateaued in 2015 (Dai & Clements, 2018). Elsewhere, Jamal et al. reported that the proportion of tobacco screening by physicians in 11-21 year-old was quite stable between 2004 and 2010 (Jamal, Dube, Babb, & Malarcher, 2014). They also reported no significant trend from 2005 to 2010 in outpatient hospital patients (Jamal, Dube, & King, 2015). Nelson et al. found no time trend for the level of tobacco screening of smokers with chronic diseases by primary care physicians between 2001 and 2009 (Nelson et al., 2015). Huo et al. found an increase in the percentage of smokers who discussed the topic with a healthcare professional between 2011 to 2015 (from 51.3 to 55.4 %) (Huo et al., 2020). Finally, Tibuakau et al. found that the proportion of smokers who reported receiving physician advice to quit modestly

increased between 2006-2007 and 2014-2015 (Tibuakuu et al., 2019). However, to our knowledge, no published study to date has provided data on recent trends in tobacco screening rates by GP.

In our study, systematic tobacco screening was associated with younger GP age. This was also highlighted in the 2008-2009 edition of the GP Health Barometer (Beck et al., 2011). However, these findings contrast with work by Andler et al. based on a 2015 dataset. Those authors found no relationship between French GP age and systematic tobacco screening practices for pregnant women (Andler et al., 2018). Moreover, in the US, Kruger et al. found no difference in screening prevalence according to primary care physician age group (Kruger, O'Halloran, & Rosenthal, 2015). In contrast, in Italy, Nobile et al. found that younger primary care physicians were more likely to self-report conducting smoking cessation activities for their patients (Nobile et al., 2014).

Our result regarding GP age and screening may be related to a lower perception of the tobacco-related risk of cancer observed in older adults in the French general population. (Institut National du Cancer, 2023). This perception may be especially prevalent prior to 2007, the year when the ban on smoking in public places came into effect in France. Accordingly, older GPs in our study may have faced repeated reluctance to screening from patients before this era, despite the importance of such screening being underlined during their training. This reluctance may have led to them to choose not to screen, and this practice may have continued until the present day. We can also suppose that more recent medical training included more communications skills related to this topic, and therefore increased younger GPs' ease and confidence in addressing this issue with patients.

Systematic tobacco screening was associated with working in a group practice in the present study. Group practices may foster knowledge exchange between healthcare professionals, as shown in an Australian study which highlighted that early-career GPs were likely to seek advice regarding substance use management from senior colleagues (Wilson, Norris, Tapley, Magin, & Klein, 2021). Elsewhere, inter-physician collaboration in hospital settings improved clinical outcomes (Braam, Buljac-Samardzic, Hilders, & van Wijngaarden, 2022). Previous studies have documented that GP knowledge exchange practices reduce variability in their clinical practices and thereby enhance their performance (Armeni, Compagni, & Longo, 2014; Mascia, Dandi, & Di Vincenzo, 2014; Rodriguez, Chen, Martinez, & Friedberg, 2016). In a French qualitative study, primary care physicians

identified other healthcare professionals as their main resources when considering how to manage tobacco smoking in their patients (Coindard et al., 2022).

In our analysis, using the RPIB approach was associated with systematic screening for both tobacco and cannabis. This result may imply that GPs who feel insufficiently trained to screen and/or to help patients quit, were less likely to screen for these two substances. Indeed, a lack of training was the most cited reason for not feeling comfortable talking about tobacco or alcohol with patients. Therefore, one can suppose that promoting the RPIB approach and the use of existing validated screening tools to GPs, would improve screening rates. Very few (<2%) GPs in our sample had a university diploma in addiction medicine. Shorter GP training sessions in this area have yielded positive results regarding tobacco screening and treatment in other contexts (Girvalaki et al., 2018; Verbiest et al., 2014). A similar association between familiarity with the RPIB approach and screening practices was shown for alcohol in the same survey (Barré, Di Beo, Mourad, et al., 2023).

In our study, a lack of training, a lack of self-efficacy, and facing patient denial about having at-risk use, were the three main reasons GP did not feel comfortable discussing tobacco or alcohol use with patients. These same barriers were previously reported in other studies on tobacco (Manolios et al., 2021; Zwar & Richmond, 2006), on alcohol (Aira, Kauhanen, Larivaara, & Rautio, 2003; Costa et al., 2019; Hyland, Hammarberg, Andreasson, & Jirwe, 2021; Johnson, Jackson, Guillaume, Meier, & Goyder, 2011; Lid & Malterud, 2012; Mules et al., 2012), and on the implementation of clinical practice guidelines more generally (Cabana et al., 1999; Lugtenberg, Zegers-van Schaick, Westert, & Burgers, 2009). Training, broadly speaking, may help to overcome the other two barriers cited. For instance, motivational interviewing skills may help GPs to increase patients' awareness about at-risk behaviors and motivate them to make behavioral changes (Brett, Chavarria, Liu, Hedeker, & King, 2021; Rubak, Sandbæk, Lauritzen, & Christensen, 2005; Samet, Rollnick, & Barnes, 1996; Substance Abuse and Mental Health Services Administration (US), 2019).

In our study, 34.6% of GPs systematically screened for cannabis use, which is a significant improvement on the 7.8% reported in the 2008-2009 edition of the GP Health Barometer (Beck et al., 2011). Nevertheless, it highlights a large gap with the proportion observed for systematic tobacco screening in our study (74.6%). A few elements can explain this relatively low rate. First, the prevalence of cannabis use is much lower than for tobacco in France. Specifically, in 2021, 10.6% of 18-64 year-olds had used cannabis in the previous year, and 1.7% were daily users (Le Nézet et al., 2022). This compares with a quarter of

adults who daily used tobacco. Moreover, cannabis use is heterogeneous; in 2021, men were two times more likely to have used in the previous year than women, and 18-24 year-olds were more than twice as likely to use than individuals over 35 years (Le Nézet et al., 2022). Cannabis-related risks are also strongly related to age at first use (Gorey, Kuhns, Smaragdi, Kroon, & Cousijn, 2019; Schoeler et al., 2018), older adults having a lower risk than adolescents and young adults (Hosseini & Oremus, 2019). As tobacco use is common among cannabis users (Agrawal, Budney, & Lynskey, 2012), and especially in Europe (Hindocha, Freeman, Ferris, Lynskey, & Winstock, 2016), tobacco users are also more likely to be cannabis users. In our study, a majority (54.8%) of French GPs only screened certain patients for cannabis use. Accordingly, this targeted screening may be partly justified.

Another barrier to cannabis screening may be the lack of a consensual threshold regarding 'at-risk' levels of use. Despite the fact that the risk of cannabis use disorder increases with the frequency of use (Robinson et al., 2022), and despite the existence of validated screening tools (Artigaud et al., 2020; López-Pelayo, Batalla, Balcells, Colom, & Gual, 2015), there is no national French guideline regarding at-risk or low-risk levels of use (unlike in Canada for instance) (Fischer et al., 2017; Government of Canada, 2019). Furthermore, in terms of assessing risk levels, cannabis use is criminalized in France. This situation may lead to a degree of stigmatization by GPs, resulting in their feeling less comfortable about discussing cannabis use (Barrett, Mellor, Ritter, McLauchlan, & Kearnes, 2022; Reid, 2020; Skliamis, Benschop, & Korf, 2022; Young-Wolff et al., 2022). Moreover, assessing cannabis exposure to determine the risk level is difficult, as the materials used and user practices vary greatly (Freeman & Lorenzetti, 2020). Given that the detrimental effect of cannabis use on tobacco cessation outcomes has been shown (Barré et al., 2021; Voci, Zawertailo, Baliunas, Masood, & Selby, 2020) – as has the reciprocal effect (Lemyre, Poliakova, & Bélanger, 2019) – the systematic screening of tobacco users for cannabis use may be beneficial.

Contrary to our findings for tobacco, systematic screening of cannabis use was associated with older GP age. This finding reflects studies in the US, where older age was correlated with higher risk perception in terms of cannabis use (Okaneku, Vearrier, McKeever, LaSala, & Greenberg, 2015; Pacek, Mauro, & Martins, 2015; Waddell, 2022). Higher risk perception can subsequently encourage screening for use among older GPs.

One of the strengths of the present study is the recruitment design, which ensured that our study sample was representative of French GPs. We also collected both objective (e.g., working conditions) and subjective (e.g., role legitimacy) data, which provided a more comprehensive picture of the factors influencing screening practices. Yet another strength is that we involved GPs in the survey design; this ensured that the questions asked were pertinent.

The study has a number of limitations. First, we did not collect data on GPs' personal tobacco use. Previous studies in France showed that GPs who smoked tobacco were less likely to ask their patients whether they smoked (De Col, Baron, Guillaumin, Bouquet, & Fanello, 2010; M. Underner et al., 2006; Michel Underner, Laforgue, Chabaud, & Meurice, 2004). According to another study, GPs who smoke may be less confident in their ability to help patients quit (Josseran, King, Guilbert, Davis, & Brücker, 2005). In contrast, Andler at al. found no effect of GP tobacco smoking status on the likelihood of screening pregnant women (Andler et al., 2018). Elsewhere, an Austrian study found that physicians who smoked asked patients about their tobacco use less frequently than their non-smoking counterparts (Kössler, Lanzenberger, & Zwick, 2002), and similar results were found in Finland (Barengo, Sandström, Jormanainen, & Myllykangas, 2005). These various findings suggest that had we collected data on GPs' smoking status, our analyses and therefore our results could have been more comprehensive. Tobacco smoking has been associated with male gender in GPs (Besson et al., 2021), but this variable was not associated with our outcome. Furthermore, while it is possible that tobacco smoking status would have confounded the effect of familiarity with RPIB approach, to our knowledge no such evidence exists.

A second study limitation is that we based our analyses on self-reported data, given that it is difficult to obtain an objective measurement of the screening rate (Conroy et al., 2005). Self-reported data may lead to social desirability. Indeed, we can see a discrepancy between the high reported screening rates in our study, and the above-cited patient-based figures (Cogordan et al., 2020). We can also suppose that some of the GPs solicited but who did not respond chose not to do so because they did not want it to be known that their practice did not follow official guidelines. This suggests the frequency of systematic screening was overestimated. Having said that, the study response rate was relatively high and weights applied in the analyses took into account non-response.

Finally, the questions regarding incentive-related higher screening frequency and the reasons for not feeling comfortable discussing substance use reduction/cessation included both tobacco and alcohol in their wordings, which prevented us from drawing tobacco-specific results on these elements.

To conclude, three quarters of the French GPs in our study sample reported that they systematically screened their patients for tobacco use. This proportion fell to one-third for cannabis use. These rates indicate an improvement in GP screening practices in the last two decades, and better GP training could be a major lever to ensure this trend remains.

Compliance with Ethical Standards

Conflict of Interest

All authors declare they have no conflict of interest.

Informed consent

The survey was conducted in accordance with the Declaration of Helsinki. In line with French law, no written consent was required as the survey was anonymous.

References

- Agrawal, A., Budney, A. J., & Lynskey, M. T. (2012). The co-occurring use and misuse of cannabis and tobacco: A review. *Addiction (Abingdon, England)*, *107*(7), 1221–1233. https://doi.org/10.1111/j.1360-0443.2012.03837.x
- Aira, M., Kauhanen, J., Larivaara, P., & Rautio, P. (2003). Factors influencing inquiry about patients' alcohol consumption by primary health care physicians: Qualitative semi-structured interview study. *Family Practice*, *20*(3), 270–275. https://doi.org/10.1093/fampra/cmg307
- Andler, R., Cogordan, C., Pasquereau, A., Buyck, J.-F., & Nguyen-Thanh, V. (2018). The practices of
 French general practitioners regarding screening and counselling pregnant women for
 tobacco smoking and alcohol drinking. *International Journal of Public Health*, 63(5), 631–640.
 https://doi.org/10.1007/s00038-018-1103-9
- Armeni, P., Compagni, A., & Longo, F. (2014). Multiprofessional Primary Care Units: What Affects the Clinical Performance of Italian General Practitioners? *Medical Care Research and Review: MCRR*, 71(4), 315–336. https://doi.org/10.1177/1077558714536618
- Artigaud, L., Fener, C., Bisch, M., Schwan, R., Schwitzer, T., De Ternay, J., ... Laprévote, V. (2020).
 [Screening tools for cannabis use disorders and their adaptation to DSM-5: A literature review]. *L'Encephale*, 46(5), 382–389. https://doi.org/10.1016/j.encep.2020.02.010
- Assurance Maladie. (2023, January 11). Rosp médecin traitant de l'adulte. Retrieved 17 March 2023, from https://www.ameli.fr/medecin/exercice-liberal/facturationremuneration/remuneration-objectifs/medecin-traitant-adulte
- Barbosa, C., Cowell, A., Dunlap, L., Wedehase, B., Dušek, K., Schwartz, R. P., ... Mitchell, S. G. (2022).
 Costs and Implementation Effectiveness of Generalist Versus Specialist Models for
 Adolescent Screening and Brief Intervention in Primary Care. *Journal of Studies on Alcohol and Drugs*, *83*(2), 231–238. https://doi.org/10.15288/jsad.2022.83.231

- Barengo, N. C., Sandström, H. P., Jormanainen, V. J., & Myllykangas, M. T. (2005). Attitudes and behaviours in smoking cessation among general practitioners in Finland 2001. *Sozial- Und Praventivmedizin*, 50(6), 355–360. https://doi.org/10.1007/s00038-005-4097-z
- Barré, T., Di Beo, V., Mourad, A., Herault, T., Buyck, J.-F., Beck, F., ... Verger, P. (2023). Screening for alcohol use in primary care assessing French general practitioner practices (in press). *Alcohol And Alcoholism*. https://doi.org/10.1093/alcalc/agad067
- Barré, T., Di Beo, V., Roux, P., Mourad, A., Verger, P., Fressard, L., ... Carrieri, P. (2023). Screening for alcohol use in primary care: Assessing French general practitioner practices. *Alcohol and Alcoholism*, agad067. https://doi.org/10.1093/alcalc/agad067
- Barré, T., Mercié, P., Marcellin, F., Esterle, L., Duvivier, C., Teicher, E., ... ANRS CO13 HEPAVIH Study
 Group. (2021). HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts
 in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). *AIDS and Behavior*.
 https://doi.org/10.1007/s10461-021-03277-x
- Barrett, L., Mellor, R., Ritter, A., McLauchlan, L., & Kearnes, M. (2022). Navigating the grey:
 Experiences of incremental cannabis reform in Australia. *Drug and Alcohol Review*, 41(7), 1621–1629. https://doi.org/10.1111/dar.13518
- Bartsch, A.-L., Härter, M., Niedrich, J., Brütt, A. L., & Buchholz, A. (2016). A Systematic Literature Review of Self-Reported Smoking Cessation Counseling by Primary Care Physicians. *PloS One*, *11*(12), e0168482. https://doi.org/10.1371/journal.pone.0168482
- Beck, F., Guignard, R., Obradovic, I., Gautier, A., & Karila, L. (2011). [Increasing trends in screening for addictives behaviors among general practitioners in France]. *Revue D'epidemiologie Et De Sante Publique*, 59(5), 285–294. https://doi.org/10.1016/j.respe.2011.03.059
- Besson, A., Tarpin, A., Flaudias, V., Brousse, G., Laporte, C., Benson, A., ... Dutheil, F. (2021). Smoking Prevalence among Physicians: A Systematic Review and Meta-Analysis. *International Journal of Environmental Research and Public Health*, *18*(24), 13328. https://doi.org/10.3390/ijerph182413328

Braam, A., Buljac-Samardzic, M., Hilders, C. G. J. M., & van Wijngaarden, J. D. H. (2022). Collaboration
 Between Physicians from Different Medical Specialties in Hospital Settings: A Systematic
 Review. Journal of Multidisciplinary Healthcare, 15, 2277–2300.
 https://doi.org/10.2147/JMDH.S376927

- Brett, E. I., Chavarria, J., Liu, M., Hedeker, D., & King, A. C. (2021). Effects of a brief motivational smoking intervention in non-treatment seeking disadvantaged Black smokers. *Journal of Consulting and Clinical Psychology*, 89(4), 241–250. https://doi.org/10.1037/ccp0000629
- Cabana, M. D., Rand, C. S., Powe, N. R., Wu, A. W., Wilson, M. H., Abboud, P. A., & Rubin, H. R. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA*, *282*(15), 1458–1465. https://doi.org/10.1001/jama.282.15.1458
- Cogordan, C., Quatremère, G., Andler, R., Guignard, R., Richard, J. B., & Nguyen-Thanh, V. (2020). [Dialogue between general practitioner and patient regarding tobacco and alcohol consumption, from the patient's standpoint]. *Revue D'epidemiologie Et De Sante Publique*, *68*(6), 319–326. https://doi.org/10.1016/j.respe.2020.10.005
- Coindard, G., Acquadro, M., Chaumont, R., Arnould, B., Boisnault, P., Collignon-Portes, R., ... Aubin, H.-J. (2022). Attitudes & behaviors toward the management of tobacco smoking patients: Qualitative study with French primary care physicians. *BMC Primary Care*, *23*(1), 10. https://doi.org/10.1186/s12875-021-01620-8
- Coleman, T. (2010). Do financial incentives for delivering health promotion counselling work? Analysis of smoking cessation activities stimulated by the quality and outcomes framework. *BMC Public Health*, *10*, 167. https://doi.org/10.1186/1471-2458-10-167
- Conroy, M. B., Majchrzak, N. E., Silverman, C. B., Chang, Y., Regan, S., Schneider, L. I., & Rigotti, N. A. (2005). Measuring provider adherence to tobacco treatment guidelines: A comparison of electronic medical record review, patient survey, and provider survey. *Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, 7 Suppl 1*, S35-43. https://doi.org/10.1080/14622200500078089

- Costa, M., Barré, T., Coste, M., Yaya, I., Berenger, C., Tanti, M., ... Carrieri, P. M. (2020). Screening and care for alcohol use disorder in France: Expectations, barriers and levers using a mixedmethods approach. *BMC Public Health*, *20*(1), 358. https://doi.org/10.1186/s12889-020-08495-x
- Costa, M., Yaya, I., Mora, M., Marcellin, F., Villotitch, A., Berenger, C., ... Carrieri, P. M. (2019).
 Barriers and levers in screening and care for alcohol use disorders among French general practitioners: Results from a computer-assisted telephone interview-based survey.
 Alcoholism Treatment Quarterly, *37*(2), 207–224.
 https://doi.org/10.1080/07347324.2018.1514989
- Dai, H., & Clements, M. (2018). Trends in Healthcare Provider Advice on Youth Tobacco Use, 2011-2015. *American Journal of Preventive Medicine*, *55*(2), 222–230. https://doi.org/10.1016/j.amepre.2018.04.015
- David, S., Buyck, J.-F., & Metten, M.-A. (2021). *Les médecins généralistes face aux conduites addictives de leurs patients* (Les dossiers de la DREES No. 80). DREES. Retrieved from DREES website: https://drees.solidarites-sante.gouv.fr/sites/default/files/2021-07/DD80.pdf
- De Col, P., Baron, C., Guillaumin, C., Bouquet, E., & Fanello, S. (2010). Le tabagisme des médecins généralistes a-t-il une influence sur l'abord du tabac en consultation en 2008 ? Enquête auprès de 332 médecins généralistes du Maine-et-Loire. *Revue Des Maladies Respiratoires*, 27(5), 431–440. https://doi.org/10.1016/j.rmr.2010.03.001
- Degenhardt, L., Ferrari, A. J., Calabria, B., Hall, W. D., Norman, R. E., McGrath, J., ... Vos, T. (2013). The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: Results from the GBD 2010 study. *PloS One*, *8*(10), e76635. https://doi.org/10.1371/journal.pone.0076635
- Delpech, R., Bloy, G., Panjo, H., Falcoff, H., Ringa, V., & Rigal, L. (2020). Physicians' preventive practices: More frequently performed for male patients and by female physicians. *BMC Health Services Research*, *20*(1), 331. https://doi.org/10.1186/s12913-020-05136-2

Direction de la recherche, des études, de l'évaluation et des statistiques. (2020, July 28). Le panel d'observation des pratiques et des conditions d'exercice en médecine générale. Retrieved 18 January 2023, from https://drees.solidarites-sante.gouv.fr/sources-outils-et-enquetes/00-lepanel-dobservation-des-pratiques-et-des-conditions-dexercice-en#toc-m-thodologie

Feingold, D., Livne, O., Rehm, J., & Lev-Ran, S. (2020). Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. *Drug and Alcohol Review*, 39(2), 142–151. https://doi.org/10.1111/dar.13031

Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., ... Room, R. (2017). Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. *American Journal of Public Health*, *107*(8), e1–e12.

https://doi.org/10.2105/AJPH.2017.303818

- Freeman, T. P., & Lorenzetti, V. (2020). 'Standard THC units': A proposal to standardize dose across all cannabis products and methods of administration. *Addiction (Abingdon, England)*, 115(7), 1207–1216. https://doi.org/10.1111/add.14842
- GBD 2015 Tobacco Collaborators. (2017). Smoking prevalence and attributable disease burden in 195
 countries and territories, 1990-2015: A systematic analysis from the Global Burden of Disease
 Study 2015. Lancet (London, England), 389(10082), 1885–1906.
 https://doi.org/10.1016/S0140-6736(17)30819-X

Girvalaki, C., Papadakis, S., Vardavas, C., Pipe, A. L., Petridou, E., Tsiligianni, I., & Lionis, C. (2018).
Training General Practitioners in Evidence-Based Tobacco Treatment: An Evaluation of the Tobacco Treatment Training Network in Crete (TiTAN-Crete) Intervention. *Health Education* & Behavior: The Official Publication of the Society for Public Health Education, 45(6), 888– 897. https://doi.org/10.1177/1090198118775481

Gorey, C., Kuhns, L., Smaragdi, E., Kroon, E., & Cousijn, J. (2019). Age-related differences in the impact of cannabis use on the brain and cognition: A systematic review. *European Archives of*

Psychiatry and Clinical Neuroscience, 269(1), 37–58. https://doi.org/10.1007/s00406-019-00981-7

Government of Canada. (2019). Canada's lower-risk cannabis use guidelines. Retrieved 4 September 2023, from https://www.canada.ca/en/health-canada/services/drugs-

medication/cannabis/resources/lower-risk-cannabis-use-guidelines.html

Haute Autorité de Santé. (2014a). Arrêt de la consommation de tabac: Du dépistage individuel au maintien de l'abstinence en premier recours. HAS. Retrieved from HAS website: https://www.has-sante.fr/upload/docs/application/pdf/2014-01/recommandations_-_arret_de_la_consommation_de_tabac.pdf

Haute Autorité de Santé. (2014b). *Repérage précoce et intervention brève en alcoologie en premier recours* [Note de cadrage]. Retrieved from https://www.has-

sante.fr/upload/docs/application/pdf/2014-

04/reperage_precoce_et_intervention_breve_en_alcoologie_en_premier_recours_-_note_de_cadrage.pdf

Haute Autorité de Santé. (2021). Outil d'aide au repérage précoce et intervention brève: Alcool,
 cannabis, tabac chez l'adulte (Screening tool for early detection and brief intervention). HAS.
 Retrieved from HAS website: https://www.has-sante.fr/jcms/c_1795221/fr/outil-d-aide-au reperage-precoce-et-intervention-breve-alcool-cannabis-tabac-chez-l-adulte

Haute Autorité de Santé. (2023). Arrêt de la consommation de tabac: Du dépistage individuel au maintien de l'abstinence en premiers recours—Actualisation [NOTE DE CADRAGE]. Retrieved from https://www.has-sante.fr/upload/docs/application/pdf/2023-

07/reco_actualisation_arret_tabac.pdf

Hindocha, C., Freeman, T. P., Ferris, J. A., Lynskey, M. T., & Winstock, A. R. (2016). No Smoke without
Tobacco: A Global Overview of Cannabis and Tobacco Routes of Administration and Their
Association with Intention to Quit. *Frontiers in Psychiatry*, *7*.
https://doi.org/10.3389/fpsyt.2016.00104

- Holmberg, C., Sarganas, G., Mittring, N., Braun, V., Dini, L., Heintze, C., ... Müller-Nordhorn, J. (2014). Primary prevention in general practice – views of German general practitioners: A mixedmethods study. *BMC Family Practice*, *15*(1), 103. https://doi.org/10.1186/1471-2296-15-103
- Hosseini, S., & Oremus, M. (2019). The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie*, *64*(5), 304–312. https://doi.org/10.1177/0706743718809339
- Huo, J., Chung, T. H., Kim, B., Deshmukh, A. A., Salloum, R. G., & Bian, J. (2020). Provider-Patient
 Discussions About Smoking and the Impact of Lung Cancer Screening Guidelines: NHIS 20112015. Journal of General Internal Medicine, 35(1), 43–50. https://doi.org/10.1007/s11606019-05111-6
- Hyland, K., Hammarberg, A., Andreasson, S., & Jirwe, M. (2021). Treatment of alcohol dependence in Swedish primary care: Perceptions among general practitioners. *Scandinavian Journal of Primary Health Care*, *39*(2), 247–256. https://doi.org/10.1080/02813432.2021.1922834
- Institut National du Cancer. (2023). Baromètre Cancer 2021. Attitudes et comportements des Français face au cancer. Retrieved 18 July 2023, from https://www.santepubliquefrance.fr/import/barometre-cancer-2021.-attitudes-etcomportements-des-francais-face-au-cancer
- Jamal, A., Dube, S. R., Babb, S. D., & Malarcher, A. M. (2014). *Tobacco Use Screening and Cessation Assistance During Physician Office Visits Among Persons Aged 11–21 Years—National Ambulatory Medical Care Survey, United States, 2004–2010* [Morbidity and Mortality Weekly Report]. National Center for Chronic Disease Prevention and Health Promotion, CDC. Retrieved from National Center for Chronic Disease Prevention and Health Promotion, CDC website: https://www.cdc.gov/mmwr/preview/mmwrhtml/su6302a11.htm#Fig
- Jamal, A., Dube, S. R., & King, B. A. (2015). Tobacco Use Screening and Counseling During Hospital Outpatient Visits Among US Adults, 2005-2010. *Preventing Chronic Disease*, *12*, E132. https://doi.org/10.5888/pcd12.140529

- Janssen, F., El Gewily, S., & Bardoutsos, A. (2021). Smoking epidemic in Europe in the 21st century. *Tobacco Control*, *30*(5), 523–529. https://doi.org/10.1136/tobaccocontrol-2020-055658
- Johnson, M., Jackson, R., Guillaume, L., Meier, P., & Goyder, E. (2011). Barriers and facilitators to implementing screening and brief intervention for alcohol misuse: A systematic review of qualitative evidence. *Journal of Public Health*, *33*(3), 412–421.

https://doi.org/10.1093/pubmed/fdq095

- Josseran, L., King, G., Guilbert, P., Davis, J., & Brücker, G. (2005). Smoking by French general practitioners: Behaviour, attitudes and practice. *European Journal of Public Health*, *15*(1), 33– 38. https://doi.org/10.1093/eurpub/cki108
- Kössler, W., Lanzenberger, M., & Zwick, H. (2002). Smoking habits of office-based general practitioners and internists in Austria and their smoking cessation efforts. *Wiener Klinische Wochenschrift*, *114*(17–18), 762–765.
- Kruger, J., O'Halloran, A., & Rosenthal, A. (2015). Assessment of compliance with U.S. Public Health Service clinical practice guideline for tobacco by primary care physicians. *Harm Reduction Journal*, *12*, 7. https://doi.org/10.1186/s12954-015-0044-3
- Laporte, C., Vaillant-Roussel, H., Pereira, B., Blanc, O., Eschalier, B., Kinouani, S., ... Vorilhon, P. (2017). Cannabis and Young Users-A Brief Intervention to Reduce Their Consumption (CANABIC): A Cluster Randomized Controlled Trial in Primary Care. *Annals of Family Medicine*, *15*(2), 131–139. https://doi.org/10.1370/afm.2003

Le Nézet, O., Spilka, S., Lahaie, E., & Andler, R. (2022). *Les usages de cannabis en population adulte en 2021*. OFDT. Retrieved from OFDT website: https://www.ofdt.fr/publications/collections/tendances/les-usages-de-cannabis-en-population-adulte-en-2021-tendances-n-153-decembre-2022/

Lemyre, A., Poliakova, N., & Bélanger, R. E. (2019). The Relationship Between Tobacco and Cannabis Use: A Review. *Substance Use & Misuse*, *54*(1), 130–145. https://doi.org/10.1080/10826084.2018.1512623 Lid, T. G., & Malterud, K. (2012). General practitioners' strategies to identify alcohol problems: A focus group study. *Scandinavian Journal of Primary Health Care*, 30(2), 64–69. https://doi.org/10.3109/02813432.2012.679229

- López-Pelayo, H., Batalla, A., Balcells, M. M., Colom, J., & Gual, A. (2015). Assessment of cannabis use disorders: A systematic review of screening and diagnostic instruments. *Psychological Medicine*, 45(6), 1121–1133. https://doi.org/10.1017/S0033291714002463
- Lugtenberg, M., Zegers-van Schaick, J. M., Westert, G. P., & Burgers, J. S. (2009). Why don't physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. *Implementation Science: IS*, *4*, 54. https://doi.org/10.1186/1748-5908-4-54
- Manolios, E., Sibeoni, J., Teixeira, M., Révah-Levy, A., Verneuil, L., & Jovic, L. (2021). When primary care providers and smokers meet: A systematic review and metasynthesis. *Npj Primary Care Respiratory Medicine*, *31*(1), 1–8. https://doi.org/10.1038/s41533-021-00245-9
- Manthey, J. (2019). Cannabis use in Europe: Current trends and public health concerns. *The International Journal on Drug Policy*, *68*, 93–96.

https://doi.org/10.1016/j.drugpo.2019.03.006

- Mascia, D., Dandi, R., & Di Vincenzo, F. (2014). Professional networks and EBM use: A study of interphysician interaction across levels of care. *Health Policy (Amsterdam, Netherlands), 118*(1), 24–36. https://doi.org/10.1016/j.healthpol.2014.06.003
- Ministère des Affaires sociales, de la Santé et des Droits des femmes. (2014). *Programme national de réduction du tabagisme 2014-2019* [Plan Cancer 2014-2019]. Retrieved from https://sante.gouv.fr/IMG/pdf/PNRT2014-2019.pdf
- Ministère des Solidarités et de la Santé, & Ministère de l'Action et des Comptes publics. (2018). *Conduire des actions visant à lutter contre le tabac*. Retrieved from https://sante.gouv.fr/IMG/pdf/180702-pnlt_def.pdf

- Mules, T., Taylor, J., Price, R., Walker, L., Singh, B., Newsam, P., ... Fouge, G. (2012). Addressing patient alcohol use: A view from general practice. *Journal of Primary Health Care*, 4(3), 217–222. https://doi.org/10.1071/hc12217
- Nelson, K. E., Hersh, A. L., Nkoy, F. L., Maselli, J. H., Srivastava, R., & Cabana, M. D. (2015). Primary care physician smoking screening and counseling for patients with chronic disease. *Preventive Medicine*, 71, 77–82. https://doi.org/10.1016/j.ypmed.2014.11.010
- Nobile, C. G. A., Bianco, A., Biafore, A. D., Manuti, B., Pileggi, C., & Pavia, M. (2014). Are primary care physicians prepared to assist patients for smoking cessation? Results of a national Italian cross-sectional web survey. *Preventive Medicine*, *66*, 107–112. https://doi.org/10.1016/j.ypmed.2014.06.009
- Okaneku, J., Vearrier, D., McKeever, R. G., LaSala, G. S., & Greenberg, M. I. (2015). Change in perceived risk associated with marijuana use in the United States from 2002 to 2012. *Clinical Toxicology (Philadelphia, Pa.), 53*(3), 151–155.

https://doi.org/10.3109/15563650.2015.1004581

- Pacek, L. R., Mauro, P. M., & Martins, S. S. (2015). Perceived risk of regular cannabis use in the United States from 2002 to 2012: Differences by sex, age, and race/ethnicity. *Drug and Alcohol Dependence*, 149, 232–244. https://doi.org/10.1016/j.drugalcdep.2015.02.009
- Paraponaris, A. (2007). La medecine générale face à ses nouvelles missions de santé publique.
 Rennes: Ecole Nationale de la Santé Publique. Retrieved from Ecole Nationale de la Santé
 Publique website: https://documentation.ehesp.fr/memoires/2007/mip/groupe_10.pdf
- Pasquereau, A., Andler, R., Guignard, R., Soullier, N., Beck, F., & Nguyen-Thanh, V. (2023).
 [Prevalence of smoking and vaping in mainland France in 2022 among 18-75 year-olds].
 Bulletin Épidémiologique Hebdomadaire, 9–10, 152–158.
- Reid, M. (2020). A qualitative review of cannabis stigmas at the twilight of prohibition. *Journal of Cannabis Research*, *2*, 46. https://doi.org/10.1186/s42238-020-00056-8

Richards, J. E., Bobb, J. F., Lee, A. K., Lapham, G. T., Williams, E. C., Glass, J. E., ... Bradley, K. A. (2019).
Integration of screening, assessment, and treatment for cannabis and other drug use
disorders in primary care: An evaluation in three pilot sites. *Drug and Alcohol Dependence*,
201, 134–141. https://doi.org/10.1016/j.drugalcdep.2019.04.015

Robinson, T., Ali, M. U., Easterbrook, B., Coronado-Montoya, S., Daldegan-Bueno, D., Hall, W., ...
Fischer, B. (2022). Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis. *Drug and Alcohol Dependence*, *238*, 109582.
https://doi.org/10.1016/j.drugalcdep.2022.109582

- Rodriguez, H. P., Chen, X., Martinez, A. E., & Friedberg, M. W. (2016). Availability of primary care team members can improve teamwork and readiness for change. *Health Care Management Review*, 41(4), 286–295. https://doi.org/10.1097/HMR.000000000000082
- Rosell-Murphy, M., Rodriguez-Blanco, T., Morán, J., Pons-Vigués, M., Elorza-Ricart, J. M., Rodríguez,
 J., ... Bolíbar, B. (2015). Variability in screening prevention activities in primary care in Spain:
 A multilevel analysis. *BMC Public Health*, *15*, 473. https://doi.org/10.1186/s12889-015-1767-
- Rouillon, M., Laporte, C., Ingrand, P., Castéra, P., Di Patrizio, P., Messaadi, N., ... Dupouy, J. (2021).
 Perceptions, professional responsibility and management experiences of patients with alcohol, tobacco and opioid use disorder by residents in general practice and teaching general practitioners. *The European Journal of General Practice*, *27*(1), 77–82.
 https://doi.org/10.1080/13814788.2021.1917542
- Rubak, S., Sandbæk, A., Lauritzen, T., & Christensen, B. (2005). Motivational interviewing: A systematic review and meta-analysis. *The British Journal of General Practice*, *55*(513), 305–312.

Samet, J. H., Rollnick, S., & Barnes, H. (1996). Beyond CAGE: A Brief Clinical Approach After Detection of Substance Abuse. Archives of Internal Medicine, 156(20), 2287–2293. https://doi.org/10.1001/archinte.1996.00440190027002

- Schoeler, T., Theobald, D., Pingault, J.-B., Farrington, D. P., Coid, J. W., & Bhattacharyya, S. (2018).
 Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: Findings from 40 years of follow-up. *Psychological Medicine*, *48*(13), 2169–2176.
 https://doi.org/10.1017/S0033291717003658
- Shao, H., Du, H., Gan, Q., Ye, D., Chen, Z., Zhu, Y., ... Chen, M. (2023). Trends of the Global Burden of Disease Attributable to Cannabis Use Disorder in 204 Countries and Territories, 1990–2019:
 Results from the Disease Burden Study 2019. *International Journal of Mental Health and Addiction*, 1–23. https://doi.org/10.1007/s11469-022-00999-4
- Skliamis, K., Benschop, A., & Korf, D. J. (2022). Cannabis users and stigma: A comparison of users from European countries with different cannabis policies. *European Journal of Criminology*, 19(6), 1483–1500. https://doi.org/10.1177/1477370820983560
- Solberg, L. I., Maciosek, M. V., Edwards, N. M., Khanchandani, H. S., & Goodman, M. J. (2006).
 Repeated tobacco-use screening and intervention in clinical practice: Health impact and cost effectiveness. *American Journal of Preventive Medicine*, *31*(1), 62–71.
 https://doi.org/10.1016/j.amepre.2006.03.013
- Solmi, M., De Toffol, M., Kim, J. Y., Choi, M. J., Stubbs, B., Thompson, T., ... Dragioti, E. (2023). Balancing risks and benefits of cannabis use: Umbrella review of meta-analyses of randomised controlled trials and observational studies. *BMJ (Clinical Research Ed.)*, *382*, e072348. https://doi.org/10.1136/bmj-2022-072348
- Substance Abuse and Mental Health Services Administration (US). (2019). Chapter 4—From Precontemplation to Contemplation: Building Readiness. In *Enhancing Motivation for Change in Substance Use Disorder Treatment: Updated 2019 [Internet]*. Substance Abuse and Mental

Health Services Administration (US). Retrieved from

https://www.ncbi.nlm.nih.gov/books/NBK571072/

- Teoli, R., Haller, D. M., Ingrand, P., & Binder, P. (2016). [Do general practitioners in Geneva (Switzerland) and Poitou-Charentes (France) have different approach to the management of addictions?]. *Sante Publique (Vandoeuvre-Les-Nancy, France), 28*(2), 187–195.
- The French Parliament. *Loi n° 2004-806 du 9 août 2004 relative à la politique de santé publique (1).*, Pub. L. No. SANX0300055L (2004).

The French Parliament. Loi n° 2004-810 du 13 août 2004 relative à l'assurance maladie (1)., (2004).

- Tibuakuu, M., Okunrintemi, V., Jirru, E., Echouffo Tcheugui, J. B., Orimoloye, O. A., Mehta, P. K., ...
 Michos, E. D. (2019). National Trends in Cessation Counseling, Prescription Medication Use, and Associated Costs Among US Adult Cigarette Smokers. *JAMA Network Open*, 2(5), e194585. https://doi.org/10.1001/jamanetworkopen.2019.4585
- Underner, M., Ingrand, P., Allouch, A., Laforgue, A. V., Migeot, V., Defossez, G., & Meurice, J. C.
 (2006). [Influence of smoking among family physicians on their practice of giving minimal smoking cessation advice]. *Revue Des Maladies Respiratoires, 23*(5 Pt 1), 426–429. https://doi.org/10.1016/s0761-8425(06)71812-5
- Underner, Michel, Laforgue, A.-V., Chabaud, F., & Meurice, J.-C. (2004). Influence du tabagisme des médecins sur la pratique du "conseil minimal": Enquête auprès de 369 médecins généralistes de la Vienne. *La Presse Médicale, 33*(14, Part 1), 927–929. https://doi.org/10.1016/S0755-4982(04)98796-9
- United Nations Office on Drugs and Crime. (2020). *World Drug Report 2020, second booklet: Drug use and health consequences*. Vienna: UNODC. Retrieved from UNODC website: https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf
- van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W., & van Laar, M. (2013). Predicting the transition from frequent cannabis use to cannabis dependence: A three-year

prospective study. Drug and Alcohol Dependence, 133(2), 352–359.

https://doi.org/10.1016/j.drugalcdep.2013.06.009

- van Rossem, C., Spigt, M. G., Kleijsen, J. R. C., Hendricx, M., van Schayck, C. P., & Kotz, D. (2015). Smoking cessation in primary care: Exploration of barriers and solutions in current daily practice from the perspective of smokers and healthcare professionals. *The European Journal of General Practice*, *21*(2), 111–117. https://doi.org/10.3109/13814788.2014.990881
- Vanheuverzwyn, A., & Roy, G. (2001). *Redressement par la macro CALMAR: Applications et pistes* d'amélioration.
- Verbiest, M. E. A., Crone, M. R., Scharloo, M., Chavannes, N. H., van der Meer, V., Kaptein, A. A., & Assendelft, W. J. J. (2014). One-hour training for general practitioners in reducing the implementation gap of smoking cessation care: A cluster-randomized controlled trial.
 Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco, *16*(1), 1–10. https://doi.org/10.1093/ntr/ntt100
- Vergier, N., Chaput, H., & Lefebvre-Hoang, I. (2017). *Déserts médicaux: Comment les définir? Comment les mesurer ?* (Les dossiers de la DREES No. 17). Paris: DREES. Retrieved from DREES website: https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-08/dd17.pdf
- Voci, S., Zawertailo, L., Baliunas, D., Masood, Z., & Selby, P. (2020). Is cannabis use associated with tobacco cessation outcome? An observational cohort study in primary care. *Drug and Alcohol Dependence*, 206, 107756. https://doi.org/10.1016/j.drugalcdep.2019.107756
- Vogt, F., Hall, S., & Marteau, T. M. (2005). General practitioners' and family physicians' negative beliefs and attitudes towards discussing smoking cessation with patients: A systematic review. Addiction (Abingdon, England), 100(10), 1423–1431. https://doi.org/10.1111/j.1360-0443.2005.01221.x
- Waddell, J. T. (2022). Age-varying time trends in cannabis- and alcohol-related risk perceptions 2002-2019. *Addictive Behaviors*, *124*, 107091. https://doi.org/10.1016/j.addbeh.2021.107091

Wilson, H. H. K., Norris, R., Tapley, A., Magin, P., & Klein, L. (2021). Role legitimacy, comfort and confidence providing tobacco, alcohol and other drug care: A cross-sectional study of Australian early-career general practitioners. *Education for Primary Care: An Official Publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors*, 32(1), 19–26.

https://doi.org/10.1080/14739879.2020.1830720

- World Health Organization. (2013). *Guidelines for implementation of Article 14*. WHO Framework Convention on Tobacco Control. Retrieved from WHO Framework Convention on Tobacco Control website: https://fctc.who.int/publications/m/item/guidelines-for-implementationof-article-14
- World Health Organization. (2014). *Toolkit for delivering the 5A's and 5R's brief tobacco interventions in primary care*. Geneva. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pdf
- Yarnall, K. S. H., Pollak, K. I., Østbye, T., Krause, K. M., & Michener, J. L. (2003). Primary care: Is there enough time for prevention? *American Journal of Public Health*, *93*(4), 635–641. https://doi.org/10.2105/ajph.93.4.635
- Young-Wolff, K. C., Foti, T. R., Green, A., Altschuler, A., Does, M. B., Jackson-Morris, M., ... Iturralde, E.
 (2022). Perceptions About Cannabis Following Legalization Among Pregnant Individuals With Prenatal Cannabis Use in California. *JAMA Network Open*, 5(12), e2246912.
 https://doi.org/10.1001/jamanetworkopen.2022.46912
- Zwar, N. A., & Richmond, R. L. (2006). Role of the general practitioner in smoking cessation. *Drug and Alcohol Review*, *25*(1), 21–26. https://doi.org/10.1080/09595230500459487

 Table 1. Study sample characteristics (n=2412)

			How often do you screen your patients for tobacco use?					How often do you screen your patients for cannabis use?					nts for	
			Don't know/ refuse to answe r (1.2%)	Never (1.1%)	Only certa in patie nts (23.0 %)	Syste matica lly, once (9.4%)	Syste mati cally, repe atedl y (65.2 %)		Don't know/ refuse to answe r 1.8%	Never 8.8%	Only certa in patie nts 54.8 %	Syste mati cally, once 11.3 %	Syste mati cally, repe atedl y 23.3 %	_
	n (%)	% weight ed ¹		% weig	ghted co	olumn		p- value ²		% weig	hted co	lumn		p- value ²
Gender								< 0.001						0.289
Men	1353 (56.1)	61.2	55.5	97.4	69.5	62.3	57.6		47.7	80.2	59.1	56.9	62.1	
Women	1059 (43.9)	38.8	44.6	2.6	30.5	37.7	42.4		52.3	19.8	40.9	43.1	37.9	
Age (years)								< 0.001						< 0.001
< 50	1040 (43.1)	32.7	27.9	12.7	20.8	37.0	36.7		55.4	13.3	38.5	34.3	23.9	
50-59	752 (31.2)	39.6	44.9	48.3	41.8	39.8	38.5		27.9	44.7	35.4	40.9	47.7	
≥60	620 (25.7)	27.7	27.3	39.0	37.4	23.2	24.8		16.8	42.1	26.1	24.9	28.4	
GP supply density³ Practice located in an area with								0.869						0.747
2.8 or more consultations per year per inhabitant	1788 (74.1)	89.6	87.1	92.3	89.1	90.2	89.7		82.0	89.0	89.9	88.5	90.1	
Practice located in an area with fewer than 2.8 consultations per	624 (25.9)	10.4	12.9	7.7	11.0	9.8	10.3		18.0	11.0	10.1	11.5	9.9	
year per inhabitant Activity volume ⁴								< 0.001						0.105
< first quartile	664 (27.5)	23.4	30.5	9.2	24.1	22.9	23.3	\0.001	17.4	22.3	22.8	25.3	24.6	0.105
\geq first and \leq third quartile	1249 (51.8)	23. 4 51.0	50.5 51.6	36.2	42.1	46.8	23.3 54.9		65.0	43.9	51.5	23.3 56.0	49.0	

> third quartile	499 (20.7)	25.7	17.9	54.6	33.8	30.3	21.8		17.6	33.8	25.8	18.8	26.4	
Currently, with regard to your main private activity, you								< 0.001						< 0.001
work:		41.0	160	7 0 0	5 < 0	41.0	07.0		477.5	<i>c</i> 1 1	07.1	22.2	10.0	
Alone	750 (31.2)	41.8	16.8	58.8	56.2	41.0	37.0		47.5	64.1	37.1	32.2	48.8	
In a group practice	1655 (68.8)	58.2	83.2	41.2	43.8	59.0	63.0		52.5	35.9	62.9	67.8	51.2	
In the last two years, have you contributed to the organization														
of collective prevention actions as part of your professional activity?								0.429						0.976
No	1791 (74.3)	79.3	85.6	81.7	79.8	82.1	78.5		84.8	77.0	79.2	79.8	79.5	
Yes	621 (25.8)	20.7	14.4	18.3	20.2	17.9	21.5		15.2	23.0	20.8	20.2	20.5	
Do you have prevention messages and/or tools available														
for patients in your consultation room (at least one of the following: flyers,								0.022						0.154
booklets, self-administered questionnaires, videos)?														
No	329 (13.7)	14.9	11.9	37.4	18.2	12.1	13.8		22.3	22.9	13.7	11.3	16.0	
Yes	2077 (86.3)	85.1	88.1	62.6	81.8	87.9	86.2		77.7	77.1	86.3	88.7	84.0	
Are you familiar with the 'early identification and brief								< 0.001						0.026
intervention' approach? ⁵ No	1506 (63.4)	66.8	58.7	96.9	78.3	70.8	61.7		58.7	82.9	68.1	60.4	61.4	
Yes, but you do not use it	269 (11.3)	10.8	16.4	1.0	10.3	7.9	11.5		14.5	6.9	10.3	13.0	12.2	
Yes and you use it	599 (25.2)	22.4	24.8	2.1	10.5	21.4	26.8		26.8	10.2	21.7	26.6	26.4	
Do you have a university	277 (20.2)		21.0	2,1	11.1	<i>2</i> 1. ľ	20.0		20.0	10.2	<i>2</i> 1./	20.0	20.1	
diploma in addiction medicine or tobacco care ?								0.049						0.069
No	2371 (98.3)	98.4	100	97.9	99.0	99.8	97.9		100	99.8	98.3	99.6	97.3	

Yes	41 (1.7)	1.6	0	2.1	1.0	0.2	2.1		0	0.2	1.7	0.5	2.7	
How often do you screen your														< 0.001
patients for tobacco use?														<0.001
Don't know/refuse to answer	30 (1.3)	1.2							25.7	0.7	0.9	1.0	0.2	
Never	20 (0.8)	1.1							0	8.7	0.7	0.2	0	
Only certain patients	478 (19.8)	23.0							10.3	50.4	28.2	9.5	8.1	
Systematically, once	259 (10.7)	9.4							11.8	3.8	9.5	26.1	3.2	
Systematically, repeatedly	1625 (67.4)	65.2							52.3	36.5	60.7	63.3	88.5	
How often do you screen your								<0.001						
patients for cannabis use?								< 0.001						
Don't know/refuse to answer	47 (2.0)	1.8	39.4	0	0.8	2.3	1.4							
Never	192 (8.0)	8.8	5.3	66.2	19.1	3.5	4.9							
Only certain patients	1307 (54.2)	54.8	42.1	32.1	67.2	55.0	51.0							
Systematically, once	318 (13.2)	11.3	9.6	1.6	4.7	31.3	11.0							
Systematically, repeatedly	548 (22.)	23.3	3.6	0	8.2	8.0	31.7							

¹Respondents' data were weighted for non-return (GP not reached) and non-response (GP declined participation), and for stratification variables (age, volume of activity category, gender, region of practice, and GP supply density).

 2 Chi-square test. Participants who refused to answer or who answered that they did not know or never performed this type of screening were excluded from the tests, in order to be able to perform the Chi-square test (i.e., to be able to meet the minimal number of observations condition in each cell)

³ Density calculated based on GPs under 65 years of age (Vergier et al., 2017)

⁴ Number of consultations in 2017

⁵ The *Repérage Précoce et Intervention Brève* (RPIB in French) is recommended by the French National Authority for Health (*Haute Autorité de Santé*) (Haute Autorité de Santé, 2014b).

	Systematic to	obacco u	se screening (n=2	(382)	Systematic cannabis use screening (n=2365)					
	Univariab	le	Multivaria	ble	Univariable	e	Multivariable			
	OR [95% CI]	P- value	aOR [95% CI]	P- value	OR [95% CI]	P- value	aOR [95% CI]	P- value		
Gender										
Men	ref				ref					
Women	1.74 [1.28-2.37]	< 0.001			1.07 [0.82-1.38]	0.626				
Age (years)										
< 50	ref		ref		ref		ref			
50-59	0.51 [0.35-0.75]	0.001	0.65 [0.44-0.96]	0.030	1.59 [1.17-2.15]	0.003	1.69 [1.24-2.30]	0.001		
≥60	0.36 [0.25-0.53]	< 0.001	0.50 [0.34-0.76]	0.001	1.23 [0.90-1.69]	0.194	1.35 [0.97-1.87]	0.072		
Area density ¹										
Practice in an area with 2.8 or more consultations per year per inhabitant Practice in an area with fewer than	ref				ref					
2.8 consultations per year per										
inhabitant	0.94 [0.73-1.22]	0.658			1.02 [0.82-1.28]	0.849				
Activity volume ²										
< first quartile	ref				ref					
\geq first and \leq third quartile	1.30 [0.90-1.87]	0.163			0.93 [0.68-1.27]	0.642				
> third quartile	0.66 [0.44-1.00]	0.049			0.81 [0.56-1.18]	0.279				
Currently, with regard to your main private activity, you work :										
Alone	ref		ref		ref					
In a group practice	2.15 [1.59-2.90]	< 0.001	1.68 [1.21-2.31]	0.002	0.90 [0.69-1.18]	0.434				

 Table 2: Factors associated with systematic screening for tobacco and cannabis use (logistic regression)

In the last two years, have you contributed to the organization of collective prevention actions as part of your professional activity?								
No	ref				ref			
Yes	1.06 [0.74-1.51]	0.762			0.96 [0.71-1.29]	0.787		
Do you have prevention messages and tools available for patients in your consultation room (at least one of the following: flyers, booklets, self-administered questionnaires, videos)? No Yes	ref 1.50 [1.00-2.25]	0.049			ref 1.04 [0.71-1.52]	0.857		
Are you familiar with the 'early identification and brief intervention' approach? ³								
No (ref.)	ref		ref		ref		ref	
Yes, but you do not use it	1.42 [0.87-2.31]	0.160	1.31 [0.80-2.12]	0.283	1.46 [0.96-2.21]	0.076	1.47 [0.97-2.23]	0.068
Yes and you use it	3.00 [1.95-4.63]	< 0.001	2.49 [1.60-3.86]	< 0.001	1.51 [1.11-2.04]	0.008	1.60 [1.18-2.18]	0.002
Do you have a university diploma in addiction medicine or tobacco care ?								
No	ref				ref			
Yes	1.73 [0.48-6.30]	0.403			1.30 [0.52-3.26]	0.570		

¹ Density calculated based on GPs under 65 years of age (Vergier et al., 2017)

² Number of consultations in 2017

³ The *Repérage Précoce et Intervention Brève* (RPIB in French) is recommended by the French National Authority for Health (*Haute Autorité de Santé*) (Haute Autorité de Santé, 2014b).

aOR, adjusted odds ratio; CI, confidence interval

			How often do y	you screen your j	patients	How often do y	vou screen your	patients	
	n (%)		for	tobacco use?		for cannabis use?			
		% weighted ¹	Not syste- matically (% weighted)	Syste- matically (% weighted)	p- value ²	Not syste- matically (% weighted)	Syste- matically (% weighted)	p- value ²	
Do you personally feel comfortable talking with patients about reducing or stopping their tobacco use? Yes, absolutely	1931 (80.2)	80.1	71.3	82.9	<0.001	77.4	85.1	<0.001	
Yes, somewhat	430 (17.9)	80.1 17.9	24.0	82.9 16.0		20.2	83.1 13.6		
No, not really / no, absolutely not	48 (2.0)	2.0	4.7	1.1		2.4	1.3		
Would you say that it is part of the physician's role to initiate discussions with tobacco smoking patients in order to offer help in stopping their tobacco use?	1000 (02 5)	01.5	60 Q	06.2	<0.001	70.4	07.5	<0.001	
Yes, absolutely	1998 (83.6)	81.7	68.2	86.2		78.6	87.5		
Yes, somewhat	363 (15.2)	17.4	30.9	12.9		20.7	11.2		
No, not really / no, absolutely not	29 (1.2)	0.9	0.9	0.9		0.7	1.2		

 Table 3. Self-reported barriers and levers to screening according to study outcomes

Do you think that the 'Remuneration on Public							
Health Objectives' has enticed you to propose the					0.006		0.493
brief intervention approach							
to patients who smoke or							
drink alcohol? ³							
No	833 (35.0)	35.3	39.1	34.1	33.5	34.4	
Yes	1416 (59.4)	58.2	52.8	60.0	57.5	59.7	
Not aware of such remuneration	135 (5.7)	6.5	8.1	5.9	6.9	6.0	

¹Respondent data were weighted for non-return (GP not reached) and non-response (GP who declined participation), and for stratification variables (age, volume of activity category, gender, region of practice, and GP supply density).

² Chi-square test

³ The *Repérage Précoce et Intervention Brève* (RPIB in French) is recommended by the French National Authority for Health (*Haute Autorité de Santé*)




Figure 1. Reasons for not feeling comfortable talking about tobacco or alcohol consumption with patients identified as having high-risk consumption (n=48)